Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias
Year: 2020
Type: article
Abstract: Various biomarkers are available to support the diagnosis of neurodegenerative diseases in clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET, which assesses brain amyloid deposition, and 18 F-fluorodeoxyglucose ( 18 F-FDG) PET, which assesses glucose metabolism, provide valuable and complementary information. However, uncertainty remains regarding the optimal timepoint, combination, and an order in which these PET biomarkers should be used in diagnostic evaluations because conclusive evidence is missing. Following an expert panel discussion, we reached an agreement on the specific use of the individual biomarkers, based on available evidence and clinical expertise. We propose a diagnostic algorithm with optimal timepoints for these PET biomarkers, also taking into account evidence from other biomarkers, for early and differential diagnosis of neurodegenerative diseases that can lead to dementia. We propose three main diagnostic pathways with distinct biomarker sequences, in which amyloid-PET and 18 F-FDG-PET are placed at different positions in the order of diagnostic evaluations, depending on clinical presentation. We hope that this algorithm can support diagnostic decision making in specialist clinical settings with access to these biomarkers and might stimulate further research towards optimal diagnostic strategies.
Source: The Lancet Neurology
Authors: Gaël Chételat, Javier Arbizu, Henryk Barthel, Valentina Garibotto, Ian Law, Silvia Morbelli, Elsmarieke van de Giessen, Federica Agosta, Frederik Barkhof, David J Brooks, Maria C Carrillo, Bruno Dubois, Anders M Fjell, Giovanni B Frisoni, Oskar Hansson, Karl Herholz, Brian F Hutton, Clifford R Jack, Adriaan A Lammertsma, Susan M Landau, Satoshi Minoshima, Flavio Nobili, Agneta Nordberg, Rik Ossenkoppele, Wim J G Oyen, Daniela Perani, Gil D Rabinovici, Philip Scheltens, Victor L Villemagne, Henrik Zetterberg, Alexander Drzezga
Institutions: Inserm, Normandie Université, Cyceron, Université de Caen Normandie, Clinica Universidad de Navarra, University Hospital Leipzig, University of Geneva, University Hospital of Geneva, Copenhagen University Hospital, Rigshospitalet, Ospedale Policlinico San Martino, Amsterdam University Medical Centers, University of Amsterdam, Vita-Salute San Raffaele University, University College London, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam, Aarhus University Hospital, Newcastle University, Alzheimer's Association, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Oslo University Hospital, University of Oslo, Lund University, Skåne University Hospital, University of Manchester, Mayo Clinic, University of California, Berkeley, University of Utah, University of Genoa, Karolinska Institutet, Humanitas University, Radboud University Nijmegen, Radboud University Medical Center, Rijnstate Hospital, University of California, San Francisco, Edith Cowan University, The University of Melbourne, Austin Health, Sahlgrenska University Hospital, UK Dementia Research Institute, UCL Queen Square Institute of Neurology, University of Gothenburg, Forschungszentrum Jülich, University of Cologne, German Center for Neurodegenerative Diseases, University Hospital Cologne
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Alzheimer's Association, Eli Lilly and Company, Biogen, American College of Radiology, European Association of Nuclear Medicine, Cerveau Technologies, National Institute for Health and Care Research, University College London, Innovative Medicines Initiative, Siemens Healthineers, Centers for Medicare and Medicaid Services, Avid Radiopharmaceuticals, UCLH Biomedical Research Centre, University College London Hospitals Biomedical Research Centre
Awards: G2293762934, G3654109730
OpenAlex ID: W3093546635